Plus, news about Zevra Therapeutics and YS Biopharma:
Skye Bioscience uplists to the Nasdaq: The San Diego biotech $SKYE is set to make the move from the OTC markets on Thursday. Earlier this year, it raised a total of about $90 million in private placements. Skye recently completed enrollment in a Phase 2a trial in glaucoma and ocular hypertension, and it plans to start an obesity and chronic kidney disease study in the middle of this year. — Kyle LaHucik
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.